Oral Plasma Kallikrein Inhibitor BCX7353 is Safe and Effective as an On-Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results of the ZENITH-1 Trial - 05/02/19
Doi : 10.1016/j.jaci.2018.12.112
Hilary Longhurst 1, Dumitru Moldovan 2, Anette Bygum 3, Marco Cicardi 4, Aarnoud Huissoon 5, Emel Aygoren-Pursun 6, Vesna Grivcheva-Panovska 7, David Hagin 8, Urs Steiner 9, Marcin Stobiecki 10, Werner Aberer 11, Claire Bethune 12, Saul N. Faust 13, Sorena Kiani 14, David Launay 15, Marcus Maurer 16, William Rae 17, Avner Reshef 18, Melanie T. Cornpropst 19, Sylvia M. Dobo 19, Sharon VanDyke 19, Sharon Murray 19, Phillip J. Collis 19, William P. Sheridan 19, Henriette Farkas 20
1 Department of Immunology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
2 Centrul Medical Mediquest, Sangeorgiu de Mures, Romania
3 Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark
4 Department of Biomedical and Clinical Sciences, Luigi Sacco Hospital, University of Milan, ASST Fatebenefratelli Sacco, Milan, Italy
5 Birmingham Heartlands Hospital, Birmingham, United Kingdom
6 Department for Children and Adolescents, Angioedema Centre, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
7 Public Health Institution University Clinic of Dermatology, School of Medicine, University Sts. Cyril and Methodius, Skopje, Macedonia, The former Yugoslav Republic of
8 Allergy and Clinical Immunology Unit, Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Israel, Tel-Aviv, Israel
9 Department of Clinical Immunology, University Hospital Zurich, Zurich, Switzerland
10 Jagiellonian University College, Krakow, Poland
11 Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
12 Department of Immunology and Allergy, Derriford Hospital, Plymouth, United Kingdom
13 NIHR Clinical Research Facility, Southampton General Hospital, Southampton, United Kingdom
14 Department of Immunology, Barts Health NHS Trust, Royal London Hospital, London, United Kingdom
15 Department of Internal Medicine, Claude Huriez Hospital, Lille, France
16 Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany
17 Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
18 Allergy, Immunology and Angioedema Center, Barzilai Medical Center, Ashkelon, Israel
19 BioCryst Pharmaceuticals, inc., Durham, NC
20 Hungarian Angioedema Reference Center, Third Department of Internal Medicine, Semmelweis University, Budapest, Hungary
110
Le texte complet de cet article est disponible en PDF.Plan
© 2018
Publié par Elsevier Masson SAS.
Vol 143 - N° 2S
P. AB36 - février 2019 Retour au numéro
Article précédent
- Sensitization To Messor barbarus Ant In A Sample Of Patients With Hymenoptera Venom Hypersensitivity
- Remedios Pérez Calderón, Nicola Giangrande, María Ángeles Gonzalo Garijo, Silvia Sánchez Vega, Mariana Marcos Fernández, Borja Bartolomé
- Recombinant Human C1 Esterase Inhibitor as Short-Term Prophylaxis for Dental Procedures in Patients With Angioedema: A Case Series
- Anna Valerieva, Maria T. Staevska, Milos Jesenak, Katarina Hrubiskova, Marta Sobotkova, Radana Zachova, Roman Hakl, Sladjana Andrejevic, Tobias M. Suiter, Vesna Grivcheva-Panovska, Ljerka Karadza-Lapic, Ralph Shapiro, Florence Ida Hsu, Andrea Zanichelli
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?